Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of arctigenin in preparation of medicines for preventing and treating bone marrow suppression caused by radiation or chemicals

A technology of arctigenin and bone marrow suppression, which is applied in the direction of drug combination, medical preparations with non-active ingredients, medical preparations containing active ingredients, etc., and can solve the problem that there are no literature reports on arctigenin, etc.

Active Publication Date: 2012-05-09
LUNAN PHARMA GROUP CORPORATION
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] There is no literature report that arctigenin has the activity of preventing and treating myelosuppression caused by radiation or chemicals

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of arctigenin in preparation of medicines for preventing and treating bone marrow suppression caused by radiation or chemicals
  • Application of arctigenin in preparation of medicines for preventing and treating bone marrow suppression caused by radiation or chemicals
  • Application of arctigenin in preparation of medicines for preventing and treating bone marrow suppression caused by radiation or chemicals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 Effect of arctigenin on bone marrow suppression induced by chemotherapy in tumor mice

[0021] 1. Animals:

[0022] Kunming mice, male and female, 7 weeks old, 18-22g, tested at (20±1)°C, humidity 40%-70%, free to drink water, and fed normally.

[0023] 2. Method:

[0024] Mouse ascites tumor s180 cells were cultured in 1640 medium, 37°C, 5% CO 2 Under conventional culture, subculture once every two days on average, and prepare a density of 3.0×10 with normal saline in the logarithmic growth phase. 7cells / ml single cell suspension, injected into the peritoneal cavity of mice under aseptic conditions, the abdominal cavity of the mice was obviously swollen 7 days after inoculation, at this time, they were killed by neck dislocation, and soaked in a beaker filled with 75% ethanol After 2-3 minutes, put the sterilized mouse into the ultra-clean workbench, expose the abdomen, extract the ascites with a sterile syringe and put it into a sterile reagent bottle for...

Embodiment 2

[0044] Example 2 arctigenin pair 60 Effect of Co-irradiated mice on blood cell count

[0045] 1. Animals:

[0046] Kunming mice, male and female, 7 weeks old, 18-22g, tested at (20±1)°C, humidity 40%-70%, free to drink water, and fed normally.

[0047] 2. Method:

[0048] In addition to the normal group, mice were irradiated with 4Gy 60 Co radiation, using a one-time irradiation. On the 3rd, 7th, and 10th day, blood was drawn from the orbital vein to detect the complete blood cell count.

[0049] The irradiated mice were randomly divided into the following model group, burdock fruit extract group and arctigenin group, with 10 mice in each group, half male and half male. Each group was treated or administered as follows.

[0050] The first group is the normal group: intraperitoneal injection of 0.9% normal saline;

[0051] The second group is the model group: intraperitoneal injection of 0.9% normal saline;

[0052] The third group is the burdock fruit extract group: 3....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of arctigenin in preparation of medicines for preventing and treating bone marrow suppression. The arctigenin has unexpected activities for enhancing immunity, promoting hemopoiesis and many other aspects. The animal in-vivo test proves that the arctigenin can obviously increase the quantity of leucocytes after chemotherapy, especially the quantity of neutrophilic granulocytes. Thus, the arctigenin is an active component capable of resisting side reactions of chemotherapy and enhancing the chemotherapeutic effect of tumors, and has very important meanings for prolonging the life time of cancer patients and improving the life quality of cancer patients.

Description

technical field [0001] The invention relates to the medical use of arctigenin extracted from arctium burdock, in particular the use of arctigenin in the preparation of medicines for preventing and treating bone marrow suppression, and belongs to the field of therapeutic activity of compounds. Background technique [0002] The human hematopoietic system is composed of a small number of bone marrow hematopoietic stem cells and different series of hematopoietic cells at different developmental stages. It is very sensitive to various physical, chemical and metabolic harmful factors in the body, such as exposure of the body to radiation or certain chemotherapy drugs, and clinically accepted Patients treated with radiotherapy and chemotherapy are extremely vulnerable to damage and suffer from different degrees of myelosuppression, which manifests as decreased peripheral blood leukocytes, decreased bone marrow proliferation function, and even aplastic anemia, which seriously harms t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P7/00A61P7/06
CPCA61K31/365A61K9/1075A61K9/146A61K9/1641A61K9/4858A61K9/4866A61K9/4891A61K47/10A61K47/14A61K47/44A61P7/00A61P7/06A61P35/00A61P43/00A61K9/107
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com